When an ongoing study that poses more than minimal risk was first approved by a convened Institutional Review Board, the board must conduct a continuing review at intervals it sets—no less often than once a year—and that review must be performed by the convened board, not a single expedited reviewer. The review re-examines the same criteria used at initial approval under 45 CFR 46.109, weighs any new information since the last review, and moves the study forward only if the board approves it again. The keyword pins three separate facts together: the study is already approved, it is still running, and its risk level and original approval pathway both shape how the renewal must be handled.

The regulatory foundation under 45 CFR 46.109(e) and 46.109(f)

The federal Common Rule, at 45 CFR 46.109(e), requires an IRB to conduct continuing review of research at intervals appropriate to the degree of risk but not less often than once per year. That same provision lets the IRB observe or have a third party observe the consent process where the board judges it necessary. The interval is a board decision, not a default auto-renewal: a study can be set for review every six months if the risk profile warrants it, and the minutes should show the interval being set deliberately.

Subsection 46.109(f) is where the 2018 revised Common Rule changed the landscape. It defines the categories of research that are exempt from continuing review—research eligible for expedited review, research that has progressed to the point where it involves only data analysis of identifiable private information, and research where the only remaining involvement is long-term follow-up—provided no additional risks are introduced. A greater-than-minimal-risk study initially approved by a convened board generally does not fit those exemptions, so continuing review stays in force.

The distinction matters because a study can migrate. A trial that enrolled and treated participants in year one may, by year three, be doing nothing but chart abstraction for safety endpoints. If no new intervention or risk is added, the IRB may determine under 46.109(f)(1)(ii) that continuing review is no longer required, document that determination, and shift to a lighter administrative check-in. The board must make and record that call; investigators cannot self-declare it.

Read the two provisions together and the practical rule emerges. Continuing review is presumed for more-than-minimal-risk research approved by a convened board, the burden falls on the IRB to justify moving a study out of continuing review, and the review interval is calibrated to risk rather than granted by habit. Anything the investigator submits should make the board's 46.109(f) analysis easy to document, because that analysis is the hinge on which the whole renewal turns.

Why "convened IRB" changes the rule for how this review can happen

Expedited review under 45 CFR 46.110 is available only for research that (a) presents no more than minimal risk and (b) falls within published expedited categories. A study that poses more than minimal risk fails the first prong outright, regardless of how routine the renewal looks. That is why a continuing review for this study cannot be delegated to the chair or a single designated reviewer—the convened board has to act, with a quorum and with the non-affiliated and non-scientific members present as 46.107 requires.

The size of the quorum is not left to guesswork. 45 CFR 46.108(b) requires the IRB to have at least five members with varying backgrounds and, at 46.108(b)(2), at least one member whose primary concerns are non-scientific and at least one who is not affiliated with the institution. For a convened continuing review of a more-than-minimal-risk study, those composition rules are not bureaucratic garnish; they are the conditions under which the vote is valid.

Voting itself has a floor. Under 46.108(d), a majority of the members present must approve the research, and the regulation explicitly bars a member involved in the study from contributing to the review or approval. So a continuing review of a study whose principal investigator sits on the board must exclude that person from deliberation and vote on their own protocol. That exclusion is one of the easiest compliance defects to spot in minutes.

Practically, the convened requirement shapes the calendar. If the board meets monthly, the investigator's renewal submission has to arrive early enough to land on an agenda before the approval lapses. Many institutions publish a hard internal cutoff—commonly 30 to 90 days before the approval expiration date, per their local HRPP policy—and missing it can leave the study in a lapse with enrollment halted. Confirm the exact cutoff with the reviewing IRB's office before scheduling anything.

What the investigator must submit before the review can begin

A continuing review package for a more-than-minimal-risk study approved by a convened board is not a one-page form. The typical institutional HRPP checklist asks for a current protocol with every amendment marked, a summary of enrollment to date against the approved targets, and a report of adverse events, unanticipated problems, and protocol deviations since the last approval. It also asks for a progress report describing what the study found and what it still needs to accomplish.

The consent documents have to reflect the current version used for the most recent enrollees, not the version filed at initial approval. If the board approved a consent addendum mid-year, that addendum belongs in the renewal packet. Similarly, if the study added a sub-investigator, changed sites, or modified the statistical analysis plan, those changes are part of the history the board reviews.

The tricky edge case is a study with almost no new activity in the prior year. Common Rule commentary and OHRP guidance have long noted that a dormant study still needs a documented review. Some boards then recommend that the investigator either close out the study or accept a shorter review interval until activity resumes, because "nothing changed" is not the same as "no review required" under 46.109(e).

Build the submission as a single narrative, not a pile of forms. The progress report should connect enrollment, safety events, and any protocol changes to the board's decisions at the last approval. If the board required an interim safety analysis before the next review, cite it in the packet with the date it was completed. The more the packet answers the board's questions before the meeting, the fewer delays result.

The risk-based review interval: setting it, shortening it, and the six-month case

The regulation sets one absolute floor—review no less often than once per year—but nothing prevents the board from requiring review every six months for a study with a signal of harm, a novel intervention, or a vulnerable population, and OHRP has long endorsed risk-calibrated intervals in guidance. What the interval should never be is an institutional default applied without thought. The board's minutes should show the interval chosen and, ideally, the reason.

Consider a Phase II oncology study consenting participants with advanced disease. The board may set a six-month continuation interval while dose escalation is ongoing, then extend it to twelve months once the study has moved into long-term survival follow-up at the same risk level. That move is defensible under 46.109(f)(1)(ii) so long as the board documents it and no new risks have appeared. The investigator helps by describing the current phase and any planned changes in the progress report.

Shorter intervals also carry operational costs. Each additional review is another board meeting cycle, another set of staff hours, and another chance to miss a submission deadline. Sponsors and sites sometimes argue for the longest interval the regulations allow, but the board's risk judgment controls. If the board wants review every six months, the study team should build that cadence into the calendar early rather than treat it as an administrative surprise.

A further wrinkle: the interval calculated at initial approval can be updated at any renewal. If the board previously set twelve months and later decides the study now warrants six, it can shorten the interval at the continuing review. Conversely, extending the interval is best done when there is evidence in the renewal packet supporting the change, such as stable enrollment and no safety signals in the prior period.

Reapplying the 46.109 criteria: the seven findings the board must make again

At a continuing review, the board effectively re-runs the approval test of 45 CFR 46.109. It must find that the risks to participants are minimized, that the risks are reasonable in relation to anticipated benefits, that selection of participants is equitable, that informed consent will be sought in a manner satisfying 46.116, that consent will be appropriately documented under 46.117, that the research plan adequately protects vulnerable participants, and where applicable, that the study meets the conditions for a clinical trial under 46.111(a)(7).

Retained records are part of this re-analysis, not a separate formality. Under 45 CFR 46.115(b), the IRB must retain the minutes of convened meetings, the approved consents, and the progress reports from the study for at least three years after completion of the research. That retention rule is what makes a mid-study continuing review traceable across staff turnover.

The most common failure is treating the seven criteria as boilerplate. A reviewer signs "no change from prior review" when the consent form changed, or when a safety event should have triggered a consent revision and did not. OHRP's 1998 guidance on continuing review (still the touchstone document institutions cite) stresses that the board is not merely checking a box; it is making fresh determinations on the same factors.

Conditional approval is available as a middle path. Under the OHRP continuing review framework, the board can approve a study pending specific minor changes, or it can require a protocol modification before renewed approval. That flexibility matters for a more-than-minimal-risk study where a consent clarification can be fixed in a week, not a full re-review cycle. The board's determination letter should write out the condition and the deadline.

New information in the renewal packet: adverse events, unanticipated problems, and protocol changes

A continuing review has to weigh what happened since the last approval, and the two categories that drive that analysis are adverse events and unanticipated problems involving risks to participants or others. Under 45 CFR 46.108(b) requirement of written procedures, the IRB must have—and apply—procedures for handling these reports. For a more-than-minimal-risk study, the renewal is where the accumulated record gets judged as a whole.

Adverse events that are expected and not serious typically do not rise to the level of unanticipated problems, but they still belong in the summary so the board can see the safety picture. Serious and unexpected suspected adverse reactions are the category that most often triggers a re-review of the risk-benefit finding. Grouping events by arm helps the board see whether one intervention is carrying the weight of the harm.

Protocol deviations are the quiet offenders. A single missed blood draw is minor; a pattern of enrolling participants who violate an inclusion criterion is not, because it can affect generalizability and safety. The renewal packet should distinguish deviations that affected participant rights or welfare from those that only affected study logistics. Board minutes typically record which category a deviation falls into.

The board action that follows is not a single verdict. It can renew with no conditions, renew with required modifications to the protocol or consent, require that participants be re-contacted for re-consent if new risk information emerged, or suspend enrollment pending investigation. OHRP's framework also permits the board to require extra monitoring. Each outcome should be written in the determination letter with the specific regulatory basis cited.

A worked example: what a renewal letter can actually say at month 12

Take a hypothetical greater-than-minimal-risk pediatric asthma study approved at a convened meeting on March 3, 2025, with continuing review set for twelve months. By January 2026 the study has enrolled 74 of 120 planned participants, logged one serious unexpected suspected adverse reaction that resolved, and filed four minor deviations. The IRB agenda meeting on February 12, 2026 reviews the packet. The determination letter might then run something like: continuing review conducted at the convened meeting of February 12, 2026, approval renewed until February 11, 2027, with the conditions that the consent form add the new adverse event language and the site report back on the corrective action plan within 60 days.

That timeline is illustrative, not a template for any specific institution; the exact dates, forms, and letter language are set by the reviewing IRB's own policies. Investigators should always confirm their IRB's current submission cutoff and letter format on the HRPP website. The example shows the shape of the review, not a shortcut.

What the letter cannot do is extend approval beyond the interval the board set. If the board renews to February 11, 2027, the study's approval expires on that date unless another review happens first. Running past that date without approval is a lapse, and continuing study activities during a lapse is a reportable event under the institution's HRPP procedures.

The example also illustrates a less obvious cost. A 12-month renewal cycle with a 60-day internal preparation window uses roughly two months of staff time per year for one study, and multiplying that across a portfolio adds up. That arithmetic is why boards now ask whether 46.109(f) applies at all, and the answer can move a study onto a much lighter follow-up path once the risk profile no longer justifies the full cycle.

When a study can leave continuing review under 46.109(f) even after starting at a convened board

The most consequential continuing review question for a long-running more-than-minimal-risk study is whether the board can move it off the full cycle. The 2018 Common Rule's 46.109(f)(1) lists three situations where continuing review is not required: research eligible for expedited review, research where the only remaining involvement is data analysis of identifiable private information, and research where the only remaining involvement is long-term follow-up of participants. In each case, no new risk can be introduced.

For a randomized controlled trial that has closed to enrollment and moved into long-term survival follow-up, the third situation is often the right fit, and boards have increasingly used it. The board must make that determination and record it, since the investigator has no unilateral authority to drop continuing review. A short amendment request summarizing the status, confirming no new intervention, and proposing the lighter follow-up is the standard route.

The complication is that "long-term follow-up" is not a self-defining phrase. A study that does annual imaging for safety is arguably still in long-term follow-up; a study that adds a new questionnaire with sensitive questions is arguably not. The board should state in the minutes why the remaining activity fits the category. If a site proposes to enroll additional participants for a follow-up component, the analysis needs to be rerun.

Grouping the review obligations here saves effort. A board that clears five follow-up-only studies onto a 46.109(f) track at one meeting has freed five future agendas for the studies that genuinely need convened review. The savings are real, and the documentation burden is largely one-time, though each study needs its own determination.

Common mistakes that cause a continuing review to fail or be tabled

The single most frequent cause of a tabled continuing review is a mismatch between what the investigator reports and what the record shows. If the consent form in the packet is version 4 but enrollment records show version 5 was used for the last three participants, the reviewer has to recess the vote until the discrepancy is resolved. Boards usually notice; it is a classic finding in OHRP determination letters.

A second common problem is failure to update the conflict-of-interest disclosures. A sub-investigator whose outside interests were disclosed at initial approval may have a new relationship that changes the analysis. The continuing review is the scheduled moment to check that those disclosures are current, both for the board and for the investigators.

The third is treating the interval as permanent. Investigators sometimes plan into year five using a twelve-month interval that the board only granted for year one. When the board shortens the interval at renewal, the site's calendar is already set. Reading the determination letter carefully at each cycle prevents a lapse.

The fourth is an incomplete response to a prior condition. If the board required a revised consent form at the last review and it never got filed, the next renewal will almost certainly be tabled until the missed condition is met. Building a tracking sheet for board conditions between review cycles makes this catchable.

FAQ

Is continuing review the same as annual review?

No—annual review is a calendar shorthand, while continuing review is the regulatory event under 45 CFR 46.109(e), and the interval can be shorter than twelve months. For a more-than-minimal-risk study approved by a convened board, the interval is set by the board based on risk, sometimes at six months. Reviewing the determination letter from the prior cycle confirms what the board actually ordered.

Can an expedited reviewer handle the continuing review if nothing changed?

For a more-than-minimal-risk study, generally no, because 45 CFR 46.110 expedited review applies only to research posing no more than minimal risk. A routine renewal of a higher-risk study still needs a convened board vote. The exception is when the IRB determines under 46.109(f) that the study has moved into a category that no longer requires continuing review, which is a separate determination.

What happens if the study team misses the renewal deadline?

The approval lapses, and study activities that require IRB approval must stop until the review is complete, unless the board has set a grace period under its own written procedures. Continuing enrollment, interventions, or even analysis of identifiable data during a lapse is a reportable event at many institutions. The exact consequences are set by the local HRPP policy, so confirm with the reviewing board's office.

Does a study with no new enrollment still need continuing review?

Often yes, because 46.109(e) is keyed to whether the study is ongoing, not whether enrollment is ongoing. The board may, at that continuing review, determine that the only remaining activities fall under 46.109(f)(1) and move the study onto a lighter follow-up track. The determination has to be documented; it is not automatic.

How long must the IRB keep the records for this review?

At least three years after completion of the research, per 45 CFR 46.115(b), which covers the minutes of convened meetings, the approved consent documents, and progress reports. That record retention rule is what allows the board to defend a renewal decision if a subsequent audit or query arises. Institution-specific retention schedules can be longer.

Who cannot vote at the convened continuing review?

Any IRB member who is involved in the study—typically the principal investigator if they serve on the board—cannot contribute to the review or approval under 45 CFR 46.108(d). That exclusion applies to continuing review as much as to initial review. The board's minutes should reflect the recusal.

Can the board renew a study with conditions?

Yes. Under the OHRP continuing review framework the board can approve pending specific minor changes, require protocol or consent modifications before renewal, or require that participants be re-contacted. The determination letter should spell out the condition and the compliance deadline. Investigators should confirm the moving parts with their HRPP office.

Does 46.109(f) apply to a study that started as more-than-minimal-risk?

It can, if the study's remaining activities fit one of the 46.109(f)(1) categories and no new risks are introduced, and if the IRB makes and documents that determination. The study does not stay on continuing review forever by its original risk label alone. A short amendment request describing the current status is the standard way to ask.

This article is general educational information about IRB continuing review under the U.S. Common Rule. It is not a legal opinion or a determination for any specific study, and it cannot substitute for advice from a qualified research-compliance professional or the reviewing IRB, whose written policies control. Studies involving children, prisoners, pregnant participants, or other protected populations, and studies subject to FDA regulations or international rules, add requirements this article does not cover. For an immediate regulatory problem with a specific study, contact your institution's research-integrity or HRPP office; for a crisis involving a participant, use local emergency services.